We found one randomised study comparing oral etoposide with intravenous vinblastine in classical KS, described above.46 We also found one small uncontrolled phase II study of oral etoposide in the treatment of 17 evaluable patients with classical KS, which reported a response rate of 76% to 100 mg daily for 3-5 days every 3 weeks.53 We found five small phase II trials of etoposide and one of teniposide in AIDS-related KS.54-59 In four small uncontrolled phase II studies of oral etoposide in AIDS-related KS, with between 14 and 41 evaluable patients, the objective response rate varied from 0 to 83%.54-56,58 In one study of infused etoposide in nine patients there was an overall partial response rate of only 22%, with one death resulting from drug toxicity.57 An uncontrolled study of 25 patients with AIDS-related KS treated with teniposide, 360 mg/m2 infused over 60 minutes, every 3 weeks, produced a partial response rate of 40%, which lasted a median of 9 weeks.59

0 0

Post a comment